māge™

by solvwellness™

Māge is a probiotic for women that contains a proprietary blend of clinically studied probiotics and a novel prebiotic that help restore balance to the female pelvic triangle: the gut, vagina, and urinary tract.



active ingredients in Māge:

Lactobacillus acidophilus La-14® & Lactobacillus rhamnosus HN001™ are supported by clinical trials showing strong oral route vaginal colonization and effectiveness in managing vaginitis, bacterial vaginosis, and vulvovaginal candidiasis.

Reference: Lactobacillus acidophilus La-14, Lactobacillus rhamnosus HN001 Oral consumption leads to vaginal detection; even 1 week after consumption was stopped[2].

Bacillus subtilis DE111® is supported by clinical trials showing strong oral route germination in the upper and lower GI tract supporting normalized digestion and regularity promoting digestive health, a precursor to vaginal and urinary tract health.

Reference: Bacillus subtilis DE111 These results reveal orally ingested B. subtilis DE111 spores are able to remain viable during transit through the stomach and germinate in the small intestine of humans within 3h of ingestion[7].

Bifidobacterium lactis HN019 (DR10)™ is supported by multiple clinical trials evidencing increased gut transit in persons with less frequent bowel movements, a precursor to vaginal and urinary tract health.

Reference: Bifidobacterium lactis HN019 supplementation is well tolerated, decreases Whole Gut Transit Time in a dose-dependent manner, and reduces the frequency of functional GI symptoms in adults[10].

PreforPro® is a novel prebiotic that aids in the propagation of probiotics. It is a bacteriophage that specifically and only attacks E. coli. It injects its DNA into the E. coli and reproduces itself until it ruptures the cell wall of the E. coli, killing it. The resulting new bacteriophages and nutrients are released into the biome. These nutrients nourish the probiotics, so they thrive and multiply 3- to 4-fold. Subsequent to successful gut transit and now well-nourished the probiotics have much larger colony counts, so are better prepared to transmigrate from the gut to the vagina and urinary tract.

Reference: PreforPro selectively reduces target organisms (E. coli) without global disruption of the gut community[14] and as a combination therapy may alter gut ecology to extend the GI benefits of consuming B. lactis or other probiotics[15].

Contact Us

For more information or to request access to the clinical studies referenced in this document, please contact us at 877.421.7160 or hcp@solvwellness.com.

Your patients will always receive the best deal on Solv Wellness products when purchasing direct from the Customer Care Team at 877.421.7160 or online at solvwellness.com. Here they will have access to new customer and trial discounts, competitive subscription pricing, and rewards.

clinical citations

Lactobacillus acidophilus La-14®, Lactobacillus rhamnosus HN001™

1. Bertuccini et al "Effects of Lactobacillus rhamnosus and Lactobacillus acidophilus on bacterial vaginal pathogens" International Journal of Immunopathology and Pharmacology 30(2).
2. Alberti et al. "Lactobacilli vaginal colonization after oral consumption of Respecta® complex: a randomized controlled pilot study"; Archives of Gynecology and Obstetrics volume 292, pages 861–867 (2015).
3. Russo et al. "Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota"; Arch Gynecol Obstet. 2018 Jul;298(1):139-145.
4. Russo et al "Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomized clinical trial" Beneficial Microbes, 2019; 10(1): 19-26.
5. Gopal et all. "In vitro adherence properties of Lactobacillus rhamnosus DR20 (HN001) and Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli" International Journal of Food Microbiology 67 2001 207–216.
6. Russo et al. "Randomized clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment" Mycoses. 2019;62:328–335.

Bacillus subtilis DE111®

7. Colom et al. "Presence and Germination of the Probiotic Bacillus subtilis DE111 in the Human Small Intestinal Tract: A Randomized, Crossover, Double-Blind, and Placebo-Controlled Study" Front. Microbiol., 02 August 2021.
8. Maher et al. "Tolerance and Effect of a Probiotic Supplement (Bacillus subtilis DE111) Delivered in Capsule Form" Food and Nutrition Sciences, 2019, 10, 626-634.
9. Cuentas et al. "The Effect of Bacillus subtilis DE111 on the Daily Bowel Movement Profile for People with Occasional Gastrointestinal Irregularity" J Prob Health 2017, 5:4.

***Bifidobacterium lactis HN019 (DR10)*™**

10. Waller et al. "Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults" Scand J Gastroenterol. 2011 Sep;46(9):1057-64.
11. Gopal et al. "Effects of the consumption of Bifidobacterium lactis HN019 (DR10) and galacto-oligosaccharides on the microflora of the gastrointestinal tract in human subjects" Nutrition Research. 2003;23:1313-1328.
12. Miller et al. "Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects" Nutrients 2017, 9, 191.

PreforPro®

13. Gindin et al. "Bacteriophage for Gastrointestinal Health (PHAGE) Study: Evaluating the Safety and Tolerability of Supplemental Bacteriophage Consumption" Journal of the American College of Nutrition; Volume 38, 2019 - Issue 1.
14. Febvre et al. "PHAGE Study: Effects of Supplemental Bacteriophage Intake on Inflammation and Gut Microbiota in Healthy Adults" Nutrients 2019, 11, 666.
15. Grubb et al. "PHAGE-2 Study: Supplemental Bacteriophages Extend Bifidobacterium animalis subsp. lactis BL04 Benefits on Gut Health and Microbiota in Healthy Adults" Nutrients 2020, 12, 2474.

contact us

For more information or to request access to the clinical studies referenced in this document, please contact us at 877.421.7160 or hcp@solvwellness.com.